These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899 [TBL] [Abstract][Full Text] [Related]
23. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma. Sakai O; Igase M; Mizuno T Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214 [TBL] [Abstract][Full Text] [Related]
24. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068 [TBL] [Abstract][Full Text] [Related]
25. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655 [TBL] [Abstract][Full Text] [Related]
26. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector. Lee HJ; Hwang SJ; Jeong EH; Chang MH J Microbiol; 2024 Jul; 62(7):555-568. PubMed ID: 38700775 [TBL] [Abstract][Full Text] [Related]
27. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878 [TBL] [Abstract][Full Text] [Related]
28. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623 [TBL] [Abstract][Full Text] [Related]
29. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Tammana S; Huang X; Wong M; Milone MC; Ma L; Levine BL; June CH; Wagner JE; Blazar BR; Zhou X Hum Gene Ther; 2010 Jan; 21(1):75-86. PubMed ID: 19719389 [TBL] [Abstract][Full Text] [Related]
30. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138 [TBL] [Abstract][Full Text] [Related]
31. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes. Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O Front Immunol; 2020; 11():1704. PubMed ID: 32849600 [TBL] [Abstract][Full Text] [Related]
32. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Hudecek M; Sommermeyer D; Kosasih PL; Silva-Benedict A; Liu L; Rader C; Jensen MC; Riddell SR Cancer Immunol Res; 2015 Feb; 3(2):125-35. PubMed ID: 25212991 [TBL] [Abstract][Full Text] [Related]
33. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368 [TBL] [Abstract][Full Text] [Related]
34. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078 [TBL] [Abstract][Full Text] [Related]
35. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927 [TBL] [Abstract][Full Text] [Related]
36. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398 [TBL] [Abstract][Full Text] [Related]
37. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295 [TBL] [Abstract][Full Text] [Related]
38. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells. Zheng Y; Yu K; Du J; Jiang L; Zhang S; Han Y; Yu P; Tan Y J Exp Clin Cancer Res; 2010 Sep; 29(1):121. PubMed ID: 20815894 [TBL] [Abstract][Full Text] [Related]
39. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616 [TBL] [Abstract][Full Text] [Related]
40. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients. Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]